Oral delivery of small RNA and DNA

被引：72

作者：

Forbes, Diane C. ^{[1
]}

Peppas, Nicholas A. ^{[1
,2
,3
]}

机构：

[1] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA

[2] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA

[3] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA

来源：

JOURNAL OF CONTROLLED RELEASE | 2012年 / 162卷 / 02期

基金：

美国国家科学基金会;

关键词：

Oral delivery; siRNA; Oligonucleotide; Clinical trial; Drug delivery; TRANSCRIPTION FACTOR DECOY; IN-VIVO; ANTISENSE OLIGONUCLEOTIDES; SIRNA DELIVERY; GENE DELIVERY; NUCLEIC-ACID; INTERFERENCE; NANOPARTICLES; THERAPEUTICS; MECHANISMS;

D O I：

10.1016/j.jconrel.2012.06.037

中图分类号：

O6 [化学];

学科分类号：

070301 [无机化学];

摘要：

The promise of short RNA or DNA segments such as siRNAs, antisense oligonucleotides, and transcription factor decoys to treat disease has prompted nearly 40 clinical trials for RNA interference (RNAi)-based therapeutics and more than 100 clinical trials for antisense oligonucleotide-based technologies; in fact, there are promising in vivo and preclinical studies for many hundreds of technologies. Current treatment strategies are largely injection-based, so effective oral delivery platforms for oligonucleotides may result in improved patient comfort and compliance. We analyze recently developed oral delivery methods for short RNA and DNA segments. (C) 2012 Elsevier B. V. All rights reserved.

引用

页码：438 / 445

页数：8

共 67 条

[1]

Agrawal S., 1996, ANTISENSE THERAPEUTI

[2]

Cellular Delivery In Vivo of siRNA-Based Therapeutics [J].

Aigner, A. .

CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (34) :3603-3619

[3]

Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity [J].

Akhtar, Saghir ;

Benter, Ibrahim .

ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) :164-182

[4]

Oral delivery of siRNA and antisense oligonucleotides [J].

Akhtar, Saghir .

JOURNAL OF DRUG TARGETING, 2009, 17 (07) :491-495

[5]

SODIUM CAPRATE ELICITS DILATATIONS IN HUMAN INTESTINAL TIGHT JUNCTIONS AND ENHANCES DRUG ABSORPTION BY THE PARACELLULAR ROUTE [J].

ANDERBERG, EK ;

LINDMARK, T ;

ARTURSSON, P .

PHARMACEUTICAL RESEARCH, 1993, 10 (06) :857-864

[6]

Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation [J].

Aouadi, Myriam ;

Tesz, Gregory J. ;

Nicoloro, Sarah M. ;

Wang, Mengxi ;

Chouinard, My ;

Soto, Ernesto ;

Ostroff, Gary R. ;

Czech, Michael P. .

NATURE, 2009, 458 (7242) :1180-U116

[7]

Nucleic Acid Recognition by the Innate Immune System [J].

Barbalat, Roman ;

Ewald, Sarah E. ;

Mouchess, Maria L. ;

Barton, Gregory M. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 :185-214

[8]

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform [J].

Bennett, C. Frank ;

Swayze, Eric E. .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 :259-293

[9]

siRNA in human cells selectively localizes to target RNA sites [J].

Berezhna, Svitlana Y. ;

Supekova, Lubica ;

Supev, Frantisek ;

Schultz, Peter G. ;

Deniz, Ashok A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7682-7687

[10]

Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease [J].

Bhavsar, M. D. ;

Amiji, M. M. .

GENE THERAPY, 2008, 15 (17) :1200-1209

← 1 2 3 4 5 6 7 →